Chapter 10

Application of Humanized Mice in Immunological Research

Wenwei Tu and Jian Zheng

Abstract

During the past decade, the development of humanized mouse models and their general applications in biomedical research greatly accelerated the translation of outcomes obtained from basic research into potential diagnostic and therapeutic strategies in clinic. In this chapter, we firstly present an overview on the history and current progress of diverse humanized mouse models and then focus on those equipped with reconstituted human immune system. The update advancement in the establishment of humanized immune system mice and their applications in the studies of the development of human immune system and the pathogenesis of multiple human immune-related diseases are intensively reviewed here, while the shortcoming and perspective of these potent tools are discussed as well. As a valuable bridge across the gap between bench work and clinical trial, progressive humanized mouse models will undoubtedly continue to play an indispensable role in the wide area of biomedical research.

Key words Humanized mice, Immunology, Immune regulation

1 Introduction

During the past century, the application of rodent animal models, especially diverse gene-engineered mouse models, provided indispensable platforms and numerous valuable information for the advances in experimental medicine and biological research. However, the gap between species is still the most challenging obstacle for translation of results from rodents to humans. With the great advancement of technology in molecular biology and gene modification, the attempt to establish “humanized” mouse models has made a leap since 1990s [1–3]. Nowadays, a wide variety of humanized mouse models have been generated and applied in nearly all fields of biomedical research [4]. In this chapter, we briefly review the history and classification of humanized mouse models and then summarize the current situation and recent advancement of their application in biomedical research, especially in the research of immune-related diseases.
In general, the “humanized mice” are composed of three main classes: human gene-expressed transgenic mice (human gene-transgenic mice), which are modified by gene knock-in or replacement technology to express one or more human specific genes; humanized mice carrying human tissue, such as the liver (humanized liver mice) in which murine hepatocytes are completely or partly replaced by infused human-original hepatocytes; humanized mice equipped with functional human immune system (humanized immune system mice), which are established on immunodeficient mice by transplanting human immune organs or cells to reconstitute human immune system in mice and thus referred to special “humanized mice.” In the following section, we briefly review the history and current advance of human gene-transgenic mice and humanized liver mice, and then focus on humanized immune system mice.

Human gene-transgenic mice are closer to gene engineered mice rather than “humanized mice.” Although the expressions of human gene or protein in transgenic mice provides the platform for studying in vivo role of specific human gene or molecule, the value of these data is limited in translational medicine due to the lack of human microenvironment and signal networks in these mice.

The most widely used human gene-transgenic mice are human leukocyte antigen (HLA)-transgenic mice [5]. These HLA-expressed transgenic mice represent a useful tool in studying in vivo TCR-restricted immune responses and thus were adopted in the studies of immune-related diseases during the first 10 years of this century. For example, HLA-A0201-transgenic mice were used in inducing CD8$^+$ T cell-restricted type I diabetes (T1D) [6] and experimental autoimmune encephalitis (EAE) [7], while HLA-DRB1-transgenic mice were applied in establishing CD4$^+$ T cell-mediated EAE [8], system lupus erythematosus (SLE) [9] and rheumatoid arthritis (RA) models [10]. More recently, the respective role of HLA-DR2 and HLA-DQ8 in EAE [11] and autoimmune diabetes [12] was also studied through transgenic mice. Meanwhile, transgenic mice with distinct HLA subtype expression favor the study of HLA-related susceptibility on specific diseases, such as EAE [13], experimental autoimmune uveitis [14], arthritis [15–17], allergic bronchopulmonary aspergillosis-like pulmonary responses [18], and celiac disease [19]. Although the application of HLA-transgenic mice has been reduced due to the simplification of diseases into specialized immune responses, the combination of HLA-transgenic technology and reconstitution of human immune system in immunodeficient mice has re-assigned them vitality in biomedical research, which will be discussed in the next section.

Other transgenic mice used in immune-related studies included humanized α1KI mice [20], humanized θ-defensins mice [21], humanized toll-like receptor (TLR) 4/MD2 mice [22],
humanized type I interferon (IFN) mice [23], and humanized tumor necrosis factor (TNF) mice [24]. Similar to HLA-transgenic mice, their combination with humanized-immune system in mice will certainly strengthen their translational capability in the future.

### 1.1.2 Humanized Liver Mice

Humanized liver mice were established as early as 2001 and mainly applied in the study of drug metabolism, excretion, toxicity [25, 26], and the in vivo activity of enzymes such as human cytochrome P450 [27]. Moreover, the establishment of chimeric mice with humanized liver accelerated the progress of the studies in hepatitis virus B [28, 29], C [30, 31], D [32], and human cytomegalovirus infection [33], which had all been blocked by the lack of optimal animal models in “pre-humanized mice time.” On the other side, Chen et al. tried to stabilize the function of cryopreserved human hepatocytes in immune competent mice through a novel system called “human ectopic artificial livers (HEALs),” which involved juxtacrine and paracrine signal in polymeric scaffolds. They claimed that mice transplanted with HEALs exhibited persistent normal liver function for weeks and thus provided a window for drug-related investigation [34]. However, the efficacy and value of humanized liver mice in the development of drug are still on debate due to the proposed side effects such as ongoing liver injury caused by transgenic and the influences on “normal metabolism” mediated by exogenous treatment [35, 36]. Apart from these, the potential application of humanized liver mice in immune-related research also deserves further exploration because liver also represents a critical component of human immune system.

### 1.1.3 Humanized Immune System Mice

The development of humanized immune system mice could be divided into three phases corresponding to the establishment of Prkdc<sup>scid</sup> (protein kinase, DNA activated, catalytic polypeptide; severe combined immunodeficiency) mutation in CB17 mice, the development of NOD (non-obese diabetic)-SCID mice, and the generation of immunodeficient mice homozygous for mutation at IL (interleukin)-2 receptor γ chain locus [2, 37]. Each breakthrough mentioned previously significantly improved the engraftment of human immune cells or pluripotent stem cells and stood as milestone on the way to “real humanized mice.” The engraftment of multiple human immune components in these mice surpassed conventional human-gene knock-in in breaking the limited viewpoint of studying specific molecules under isolated environment. This unique advantage of humanized immune system mice favors their general application in immune-related studies, and opens a window for researchers to observe the interaction among human immune cells in vivo. In the following content, we focus on the characteristics and application of these mouse models and simply refer them as “humanized mice” if not otherwise specified.
Currently, IL2γc−/− mice established on NOD/scid and recombination activating gene 2 (Rag2)−/− Balb/C background were most widely used strains for the reconstitution of human immune system in vivo [38–40]. Recently, by using bone marrow, liver, thymus (BLT) co-transplantation, Lavender et al. engrafted high levels of multi-lineage hematopoiesis and organized lymphoid tissues in C57BL/6-Rag2−/−γc−/−CD47−/− triple-knockout mice. These humanized mice sustained human cell and tissue engraftment as long as 29 weeks post-transplantation without the development of chronic graft-versus-host diseases (GVHD), and thus represented for a new advancement in establishment of humanized mice [41].

The reconstitution of functional immune system is the key to evaluate the successful establishment of humanized mice. The graft used for reconstituting human immune system includes stem cells [42], BLT [41], and peripheral blood cells [43] according to specific objectives. Generally, stem cell and BLT transplantation exhibit advantage in establishing stable multi-lineage hematopoietic cells but might need additional treatment for improving development of specific cell subpopulations. On the contrary, humanized mice established by peripheral blood cells provide a ready platform for studying the functions of mature immune cells but the length of window appropriate for research is still limited by chronic GVHD and ongoing reduced engraftment. To maximize the potential of humanized mouse model, some progresses have been made recently. Firstly, pretreatment or gene-engineering of pluripotent stem cell exhibited satisfactory effects on improving engraftment of immune cells [38, 42, 44]. Secondly, human growth factors, cytokines [44, 45] or signal regulatory protein alpha (SIRPa)-expressed [46] immunodeficient mice demonstrated superior engraftment for specific immune cell subpopulations as well. In the following paragraphs, we briefly review current status of the reconstitution of specific immune cell subpopulations in humanized mice.

Lymphocytes are most important components of immune system and thus draw a major attention. Although human peripheral blood mononuclear cells (PBMC) transplantation led to rapid reconstitution of human lymphocytes in humanized mice, it was found that after initial activation and induction of antibody production, human T cell lymphocytes enter an unresponsiveness status due to loss of human professional antigen-presenting cells (APC), which could be reversed by adoptive transfer of human APC [47] or activating organ-resident myeloid dendritic cells (DC) through poly(I:C) treating [48]. Meanwhile, stem cell-transplanted humanized mice displayed diversified T cell repertoire, but the gap between HLA and murine major histocompatibility complex (MHC) molecules prohibited the induction of efficient T cell-mediated primary immune responses in vivo [49, 50].
To overcome these problems, HLA-expressed immunodeficient mice were generated and their efficacy has been confirmed [51]. Another concern origins from Th1 and Th17 immunocompetence in humanized mice [52], which supports the utility of their application as surrogate model in transplantation rejection and autoimmunity but might cause some unwanted immune responses against murine tissue antigen as well.

Distinct from their T cell companion, reconstitution of functional B lymphocytes is generally poor in humanized mice and needed to improve in the future although their primary repertoire were principally unaltered by the differences between mouse and human stromal environments [53] and their ability to produce antigen-specific antibody was partly developed [54].

As described previously, the reconstitution of myeloid cells not only guarantees immune system intact, but also determines the development and function of both adaptive and innate lymphocytes [47, 48, 55]. Unfortunately, monocytes and other myeloid cells usually exhibit immature phenotype and impaired function in humanized mice [56], which could be partly rescued by human colony stimulating factor (CSF)-1 [57]. However, the improvements in their survival, differentiation and even migration and residence [58] are still urgently required. Besides leukocytes, other blood components also play important roles during immune response and regulation. Recently, Hu et al. established the full reconstitution of human platelets in humanized mice after depletion of murine macrophage [59], which represents for an interesting attempt in constructing a more “humanized” circulation in mice.

In summary, the optimization of humanized mouse model is still on the way and the advances in molecular biology, cellular biology, and system biology will definitely bring new era to the development of this useful tool.

## 2 Applications of Humanized Mice

The applications of humanized mice cover nearly all fields of biomedical research and here we concentrate on immune-related studies, especially those aiming at the mechanisms and translational potentials of immune regulation and suppression. We also briefly summarize the benefits brought by these potent models in tumor, infectious diseases, and vaccine studies.

### 2.1 Development of Immune System

#### 2.1.1 Lymphocytes

#### 2.1.1.1 T Cells

Benefiting from humanized mouse model established by BLT or CD34+ stem cell transplantation, research on the development of human T cells made a great progress in the past 5 years. In 2011, Choi et al. induced human CD4+CD8+ double-positive (DP) T cells, CD4+ and CD8+ single-positive (SP) T cells, CD34+CD38+CD1a- (thymus setting-progenitors, TSP),
CD34+CD38loCD1a− (early T lineage progenitors, ETP), and CD34+CD38−CD1a+ pre-T cells in liver of humanized mice by intrahepatic injection of CD34+ stem cells, establishing a wonderful platform for investigating human T cell development [60]. However, Joo et al. found that human T cells educated by murine MHC in mice without a human thymus differ from normal human T cells marked as higher expression of CD45RO and promyelocytic leukemia zinc figure protein (PLZF) regardless of similar development stages [61]. Correspondingly, Danner et al. generated HLA-DR4-expressed NOD-Rag1−/−γc−/− mice and demonstrated the critical role of HLA class II molecule for development of functional T cells by infusion with HLA-DR-matched human hematopoietic stem cells [62]. Meanwhile, the roles of IL-12 [63] and Notch [64] signals during the development of human CD4+ and CD8+ T cells were evaluated by human hematopoietic stem cell-transplanted mice. Moreover, using a human stem cell factor, granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-3-expressed NOD/scid-γc−/− mice, Billerbeck et al. found the increased accumulation of human CD4+Foxp3+ T cells in blood, spleen, bone marrow and liver. Most importantly, these CD4+Foxp3+ T cells exhibited potent suppressive capability on T cell proliferation, which made a significant contribution to study of human regulatory T cells (Treg) development in vivo [65].

2.1.1.2 B Cells

As described previously, the development of human B cells in humanized mice is relatively weak compared to T cells. In 2011, Choi et al. evaluated the efficacy of Busulfan, a chemotherapeutic agent, and claimed that it could efficiently improve the reconstitution of human specific antibody-producing B cells, T cells, macrophage, and even DC from CD34+ cord blood cells with less toxic effects [66]. On the other hand, Kim et al. found that co-transplantation of fetal bone tissue with fetal thymus could facilitate the development and reconstitution of human B cells from fetal liver-derived CD34+ cells together with T cells [67].

2.1.3 Other Lymphocytes

Besides adaptive lymphocytes like T and B cells, innate lymphocytes development-related factors were also illustrated in humanized mouse model. As early as in 2008, Huntington and Di Santo made a periodic review on the application of humanized mice in the research of NK cell development [68]. In 2011, Pek et al. further confirmed the crucial role of IL-15 in NK cell development in bone marrow and liver with humanized mouse model [69]. We believe that more studies in the development of other innate lymphocytes such as NKT, γδ-T cells and innate-like T cells (ILT) will be reported in the near future.

2.1.2 Myeloid Cells and Other Cells

Myeloid cells are generally regarded as more fragile and difficult to survive in “strange environment”, which made it attractive and subtle to improve reconstitution of these sensitive cells. The
addition of human original cytokines such as GM-CSF and IL-4 was generally accepted as an efficient way to improve DC maturation [70]. Similarly, the effects of macrophage colony-stimulating factor (M-CSF) and Fms-related tyrosine kinase (FLT)-3 ligand on promoting the development of macrophage [71], and CD141+ and CD1c+ DC [72] have also been confirmed in humanized mouse model respectively. Moreover, the development of megakaryocytes was replicated and used as index of dengue virus-infection in humanized mouse model recently [73], which also supported the multi-lineage hematopoietic cell development in humanized mice. Finally, transplantation of human stem cells from bone marrow of patients with bone marrow failure syndrome into humanized mice provided invaluable tools for evaluating novel gene-targeted therapy before clinical trial [74].

In summary, the reconstitution of diverse human immune cell populations from their pluripotent progenitors in immunodeficient mice has become a potent platform for investigating the development of human immune system while the next question is how to create a more “humanized” environment in mice for human cells [75].

2.2 Autoimmune Diseases

The advances in the study of autoimmune diseases in humanized mice, especially those T cell-mediated diseases, are always correlated with development of HLA-transgenic technology. In 1999, Bachmaier et al. generated a CD4−CD8− double-knockout mice transgenic for human CD4 and HLA-DQ6 to specifically reconstitute the human HLA-DQ6/CD4 arm in mice and established a dilated cardiomyopathy model [76], which was one of the earliest attempt for applying humanized mouse model in the study of autoimmune diseases. Using similar strategy, Eming et al. established a RA model in a HLA-DR4/human CD4/TCR combined transgenic mice with the stimulation of a RA-related human autogenic protein HCgp-39 in 2002 [77]. However, the lack of human immune system reconstitution in these models constrained their representative for the whole map occurring during autoimmune diseases. On the other side, Shultz et al. established T1D model in NOD/scid-γc−/− mice by co-transplanting with human stem cell and islet cells [78, 79]. Importantly, this group pointed out the potential of HLA-transgenic immunodeficient mice in optimization of these models and provided some interesting preliminary data [78]. Soon after, inflammatory arthritis and type 2 diabetes models were established in HLA-transgenic humanized mice by David [80] and Schultz groups [81] respectively. As we mentioned previously, T cell-mediated immune responses were generally incomplete in humanized mice established on conventional immunodeficient mice, which usually led to insignificant clinical symptoms [82] and thus limited the application of these models. The involvement of HLA not only improves the efficacy of immune responses, but also provides a platform for study of the
relationship between HLA subtypes and specific diseases susceptibility. Nevertheless, the complexity and individuality of HLA phenotypes in healthy donors or patients still remain as the biggest challenge in rebuild of physiopathology process in relatively limited HLA-expressed humanized mice.

Due to relatively weak reconstitution of human B cells in humanized mice, the establishment of B cell or antibody-mediated autoimmune diseases seems to be more difficult than those T cell-mediated autoimmune diseases. Kerekov et al. rebuilt the clinical pathogenesis in humanized mice with cells transferred from SLE patients and evaluated the potential of B cell-targeted therapy with a chimeric molecule containing a monoclonal antibody against human inhibitory complement receptor type I coupled to a decapeptide that mimic DNA antigenicity [83]. In 2012, another group led by Duffield recapitulated systemic vasculitis in humanized mice by treating them with anti-proteinase-3 IgG isolated from patients [84]. With the improvement in reconstitution of multiple components of human immune system in humanized mice, it is predictable that the induction of diverse human B cell-mediated autoimmune diseases in vivo will be accessible soon.

2.3 Transplantation-Related Diseases

Application of humanized mice models in transplantation-related diseases arises as early as the birth of humanized mice but the process is so tortuous till now due to chronic exogenous rejection and ongoing decrease of immune cells [85]. In 2001, Coates established an allogeneic skin rejection model in humanized NOD/scid chimeric mice and examined the therapeutic effects of human myeloid DC transduced with an adrenoviral IL-10 gene [86]. In 2006, Marcheix et al. rebuilt a human chronic vascular rejection model in humanized SCID/beige mice with human mesenteric arterial grafts [87]. In 2012, Yi et al. determined the suppressive capacity of in vitro-expanded human CD4+ Treg on porcine islet xenograft rejection in humanized mouse model and found the crucial role of IL-10 in Treg-mediated protection [88]. In above three studies, investigators planted solid grafts into immunodeficient mice before reconstitution of human immune system and induced rejection by infusion of mature human cells. However, the long-term outcome of these models is still not clear.

In order to further mimic clinical situation, human CD34+ stem cells were applied in establishing humanized mice. Using this strategy, three independent groups reported allogeneic islet transplantation [89], xenogeneic islet rejection [90], and xenogeneic skin rejection [91] models during 2010–2012. Unfortunately, insufficient development of immune cell populations in these humanized mice still stayed as an obstacle and even led to the failure of rejection [89]. To solve this problem, some other groups tried to develop a more “mature” human immune system in humanized mice by transplanting human peripheral blood cells.
In 2013, our group reported a novel human allogenic GVHD model established on humanized mice reconstituted with human PBMC [92]. This model reproduced typical clinical process of acute GVHD occurring during allogeneic bone marrow transplantation without apparent interruption of exogenous reactivity. Using this model, we evaluated the protective effects of human CD8+ Treg induced ex vivo by allogeneic CD40-activated B cells and found that human CD8+ Treg could inhibit GVHD and induce long-term tolerance without compromising general immunity and graft-versus-tumor (GVT) activity [92]. The potent regulatory activity of the CD8+ Treg was mainly mediated by the expression of cytotoxic lymphocyte antigen (CTLA)-4 on cell surface, while their alloantigen-specificity and the ability to induce the long-term tolerance favor their clinical application. More importantly, this strategy might reduce clinical dependence on limited HLA-match donors and largely improve the survival chance of millions of patients who are waiting for bone marrow transplantation.

Humanized mouse model undoubtedly brings new hope for transplantation research, but we also need to keep in mind that a lot of questions are still waiting to be answered on this way. As emphasized by Brehm and Shultz, keys to successful humanized mouse model included available immunodeficient mouse strains, the choice of tissue to transplant and the specific human immune cell population that can be grafted [85].

Besides autoimmune diseases and transplantation-related diseases, humanized mice models are also useful to study some other inflammatory diseases.

In 2002, Hammad et al. compared the Th2 allergic inflammation in the lung of humanized mice reconstituted with PBMC. To induce inflammatory reaction, DCs from home dust mite (HDM)-allergic patients or healthy donors were injected intratracheally and mice were then repeated exposed to aerosol of HDM. In contrast to IFN-γ secretion induced in mice receiving normal DCs, those injected with DCs from patients induced IL-4 and IL-5 production accompanied with the increase of IgE production, which represents characteristics of Th2 response [93]. In 2003, Firouzi et al. used a humanized SCID mouse model confirmed the crucial role of T cells during multiple sclerosis-associated retrovirus particle-caused brain hemorrhage [94], while Sheu et al. found that circulating IgM played the main pathogenic role in skeletal muscle ischemia-reperfusion injury based on their research on hPBL-SCID mice in 2009 [95]. In the meantime, Unsinger et al. established a sepsis model in humanized mice elevated human pro- and anti-inflammatory cytokines as well as a dramatic increase in human T and B cell apoptosis, which was generally found in patients with sepsis [96]. More recently, Vudattu et al. determined the adverse effects of anti-CTLA-4 antibody (ipilimumab) including hepatitis,
lymphadenopathy, and other inflammatory sequelae in humanized mouse model [97].

In addition to immunopathology study, humanized mouse model was also applied in studying the underlying mechanisms of injury repair. By plating retroviral vector-modified human skin on nude mice and adding human keratinocyte growth factor (KGF) to artificial wound in the skin, the re-epithelialization was significantly accelerated [98]. Although this model could not be described as “real” humanized mice because no human immune system was involved in it, this attempt initiated an innovative application of humanized mice.

Compared to satisfactory reconstitution of circulating blood cells, the successful reconstitution of mucosa immunity in humanized mice is still absent till now. Mucosa, especially respiratory and digestive tract surface, plays indispensable role in protection and immune regulation. However, the residence and exchange of immune components in the locus are still difficult to rebuild in animal models because the physiological dynamics remains largely unknown [99]. Another reason is due to their complex gnotobiotic microenvironment. To meet this requirement, Gordon’s group firstly established a humanized gnotobiotic mice by transplanting fresh or frozen adult human fecal microbial communities into germ-free C57BL/6J mice and then investigated the effect of diet on human gut microbiome [100]. Similarly, Kashyap et al. determined the relationship among diet, gastrointestinal transit and gut microbiota using the same model [101], while Macrobal et al. further compared the difference between gnotobiotic humanized mice and conventional mice urine and fecal metabolomics profiles [102]. Recently, another exciting breakthrough in immune reconstitution of the gastrointestinal tract was reported by Nochi’s group. They developed human gut-associated lymphoid tissue (GALT) in mouse cryptopatches and succeeded in generating functional intestinal immunity marked by human IgA secretion in a BLT-NOD/scid mice model [103]. The combination of this humanized mouse model and gnotobiotics transfer will greatly improve our understanding on intestinal physiology and immune regulation.

The occurrence of humanized mouse model provided a perfect platform for evaluating immunotherapy against tumor. The earliest attempts of inducing antitumor immune responses in humanized mice focused on the generation of specific antibody but the outcome varied due to unstable humanization of models [104, 105]. In the new century, researchers started to pay more attention on developing complete tumorigenicity, especially metastasis process and its relationship with stromal cells, in immunocompetent humanized mice, and made some significant advances in multiple fields like human prostate cancer [106], mixed-lineage leukemia
167, human primary squamous cell carcinoma [108], and human T-cell leukemia virus (HTLV)-induced T cell leukemia [109]. Based on these progresses, some novel immunotherapy strategies were evaluated on humanized mouse models, such as inhibitory receptor Ig-like transcript (ILT)-3 depletion or blockade in melanoma [110] and IL-15-enhanced NK cell-mediated cytotoxicity against human breast cancer [111]. Recently, our group reported a novel application of pamidronate, a phosphoantigen generally used to treat osteoporosis, in treating Epstein-Barr virus (EBV)-induced B cell lymphoproliferative disease in humanized mouse model reconstituted with human PBMC [112]. This “new application of an old drug” was mediated by expanding and activating human Vγ9Vδ2-T cells, a small cell population of human lymphocytes, which might inspire further exploration of currently available resources. More importantly, the established of donor- and tissue-specific humanized mouse tumor models will undoubtedly play an indispensable role during the development of individual therapies in the future [113].

2.5.2 Infectious Disease

2.5.2.1 HIV

The development of humanized mice represents a milestone in the history of human immunodeficiency virus (HIV) study. The new generation of humanized mice not only improved our understanding on transmission, latency, and pathogenesis of HIV [114–119], but also provided unprecedented platform for antiviral study. Besides further exploration of efficient virus-specific neutralization antibodies [120–125] and conventional antiretroviral or antimicrobial therapies [126–128] in these models, the efficacy of vectored immunophylaxis [129] and CCR5-targeted treatment [130–132] in preventing HIV transmission were evaluated as well. Meanwhile, the crucial roles of HIV-specific CD8+ T cells [133, 134] and plasmacytoid DC (pDC) [135, 136] in the replication of virus and activation of immune responses, and their potentials in targeted therapy were also investigated. Other novel immunotherapy assays performed in humanized mouse model included blockade of programmed cell death (PD)-1 receptor [137, 138], engineering HIV-resistant T cells from short-hairpin RNA (shRNA)-expressing hematopoietic stem/progenitor cells [139], and inhibition of HIV replication by a chimera containing an RNA aptamer with high binding affinity to the HIV envelop protein gp120 and virus neutralization properties and a small interfering RNA (siRNA) triggering sequence-specific degradation of HIV RNAs [140]. Moreover, a preliminary study on mechanisms underlying viral controlling in HLA-B*57 elite controller or suppressor (ES) was completed in humanized BLT mice and demonstrated that elite suppressors are capable of controlling HIV-1 due to the possession of unique host factors rather than infection with defective virus in vivo [141]. Nowadays, we could even make in-depth study on the cell dynamics in HIV-infected humanized mice model...
with the help of intravital microscopy [142]. Therefore, it is countable that the future molecular biology will bring more surprise to the efforts of gene therapy against HIV [143].

2.5.2.2 Other Infectious Disease

Except for application in HIV-related studies, humanized mouse model also brought span-new opportunities for other human infectious diseases [144], especially those blood-borne pathogen-caused diseases such as dengue virus infection [145–149], EBV infection [150–155], HCMV infection [156], HTLV infection [157], and malaria parasite infection [158]. On the other hand, humanized mouse models for Leishmaniasis [159], Salmonella Typhi infection [160, 161], herpesvirus infection [162, 163], Mycobacteria infection [164, 165], and group B Streptococcus (GBS) infection [166] have been established. These efforts fill in the lacks of suitable animal models for those human-specific pathogen-caused diseases and push forward the correlating investigations on development of prevention and treatment, although some technological obstacles like the replication of natural infection and transmission routes are still needed to resolved.

In 2011, our group used PBMC-transplanted humanized mouse model to evaluate a novel therapeutic strategy by targeting the host rather than the virus for treating influenza virus infection. We demonstrated that aminobisphosphonate can control influenza disease through boosting human Vγ9Vδ2-T cell immunity and this beneficial effect is active against viruses of varying subtypes and virulence [43]. Nevertheless, differences in the characteristics of molecules, tissues, and organs between human and mice might impair efficiency of pathogen infection and initiation of specific immune responses [167]. In 2005, Lassning et al. increased the susceptibility of mice on human coronavirus by crossing aminopeptidase N (APN), the receptor for human coronavirus (hCoV)-229E, and transgenic mice into signal transducer and activator of transcription (Stat)-1 null mice [168]. This work, together with HLA- and human cytokines/growth factor-transgenic technology [169], provided successful examples for future studying human infectious agents in humanized mice. In the next stage, improvement of versatility and variability of human immune system in humanized mouse model and application of gene-modified pathogens [170] will definitely enhance translational efficiency of these models.

2.5.3 Vaccine

The usage of humanized mice in the development of vaccines targeting human diseases including EBV, HIV-1, dengue virus, influenza virus, severe acute respiratory syndrome (SARS) corona virus, and carcino-embryonic antigen (CEA) has obtained outstanding achievements during the past decade, while the introduction of HLA transgenic immunodeficient mice further accelerated the advancement in this field [171–173]. With the improvement of immune cell population reconstitution, more and more novel vaccination protocol will be carried out in humanized mice.
3 Perspective

Compared to conventional mice and non-human primate model, humanized mice exhibit great advantage in translational potential, reproductive capacity and data repeatability, economical and ethical concerns. The increasing applications of diverse humanized mice models in biomedical research during the past two decades significantly improved our understanding on human physiological and pathological, especially immunological process at systemic, cellular, and molecular levels. This further accelerated the development of current translational medicine significantly. Nevertheless, there are several major caveats on their development remain to be dealt with, including complete replacement of murine MHC with diversified HLA molecules and efficient methodology to express corresponding growth factors and cytokines at specific time and organs [174]; how to prolong the maintenance of human engraftment, promote the development of myeloid cells and increase relatively weak quantity and quality of immune cells [175]; and the limited development of lymph nodes, inter-organ traffic of immune cells, and the reconstitution of red blood cells and granulocytes [176]. In another word, the most important issue is to find the convenient and cost-effective ways to construct appropriate human-like micro-environment including physical structure, intercellular contact and molecular signals transfer in humanized mice. It is foreseeable that knowledge exchange in the age of big data will bring an even more bright future to this advancing tool than ever.

Acknowledgment

This work was supported in part by the Area of Excellence program supported by the University Grants Committee of the Hong Kong SAR, China (AoE/M-12/06 and AoE/M-06/08).

References

1. Peault B, Weissman I, Baum C (1993) Analysis of candidate human blood stem cells in “humanized” immune-deficiency SCID mice. Leukemia 7(Suppl 2):S98–S101
2. Shultz LD, Ishikawa F, Greiner DL (2007) Humanized mice in translational biomedical research. Nat Rev Immunol 7(2):118–130
3. von Bubnoff A (2008) Mighty mice. Scientists are still improving the humanized mouse model but are optimistic about its future role in evaluating AIDS vaccine candidates. IAVI Rep 12(5):1, 8–11
4. Shultz LD et al (2011) Humanized mice as a preclinical tool for infectious disease and biomedical research. Ann N Y Acad Sci 1245:50–54
5. Taneja V, David CS (1998) HLA transgenic mice as humanized mouse models of disease and immunity. J Clin Invest 101(5):921–926
6. Niens M et al (2011) Prevention of “Humanized” diabetogenic CD8 T-cell responses in HLA-transgenic NOD mice by a multipeptide coupled-cell approach. Diabetes 60(4):1229–1236
7. Mars LT et al (2007) CD8 T cell responses to myelin oligodendrocyte glycoprotein-derived peptides in humanized HLA-A*0201-
transgenic mice. J Immunol 179(8): 5090–5098
8. Quandt JA et al (2004) Unique clinical and pathological features in HLA-DRB1*0401-restricted MBP 111-129-specific humanized transgenic mice. J Immunol 179(8): 233–234
9. Dudek NL et al (2007) T cell epitopes of the La/SSB autoantigen in humanized transgenic mice expressing the HLA class II haplotype DRB1*0301/DQB1*0201. Arthritis Rheum 56(10):3387–3398
10. Snir O et al (2011) Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1*0401-positive humanized mice and rheumatoid arthritis patients. Arthritis Rheum 63(10): 2873–2883
11. Greene MT et al (2008) Differential induction of experimental autoimmune encephalomyelitis by myelin basic protein molecular mimics in mice humanized for HLA-DR2 and an MBP(85-99)-specific T cell receptor. J Autoimmun 31(4):399–407
12. Tai N et al (2011) IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8/RIP-B7.1 mice. Clin Immunol 139(3):336–349
13. Kaushansky N et al (2009) HLA-DQB1*0602 determines disease susceptibility in a new “humanized” multiple sclerosis model in HLA-DR15 (DRB1*1501;DQB1*0602) transgenic mice. J Immunol 183(5): 3531–3541
14. Pennesi G et al (2003) A humanized model of experimental autoimmune uveitis in HLA class II transgenic mice. J Clin Invest 111(8):1711–1718
15. Behrens M et al (2011) Trans heterodimer between two non-arthritis-associated HLA alleles can predispose to arthritis in humanized mice. Arthritis Rheum 63(6):1552–1561
16. Behrens M et al (2010) Mechanism by which HLA-DR4 regulates sex-bias of arthritis in humanized mice. J Autoimmun 35(1):1–9
17. Szanto S et al (2004) Induction of arthritis in HLA-DR4-humanized and HLA-DQ8-humanized mice by human cartilage proteoglycan aggrecan but only in the presence of an appropriate (non-MHC) genetic background. Arthritis Rheum 50(6):1984–1995
18. Koehn S et al (2007) HLA-DRB1 alleles control allergic bronchopulmonary aspergillosis-like pulmonary responses in humanized transgenic mice. J Allergy Clin Immunol 120(3):570–577
19. de Kauwe AL et al (2009) Resistance to celiac disease in humanized HLA-DR3-DQ2-transgenic mice expressing specific anti-gliadin CD4+ T cells. J Immunol 182(12): 7440–7450
20. Sanchez D et al (2011) Similarity of fine specificity of IgA anti-gliadin antibodies between patients with celiac disease and humanized alpha1KI mice. J Agric Food Chem 59(7): 3092–3100
21. Welkos S et al (2011) Humanized theta-defensins (retrocyclins) enhance macrophage performance and protect mice from experimental anthrax infections. Antimicrob Agents Chemother 55(9):4238–4250
22. Hajjar AM et al (2012) Humanized TLR4/MD-2 mice reveal LPS recognition differentially impacts susceptibility to Yersinia pestis and Salmonella enterica. PLoS Pathog 8(10): e1002963
23. Harari D et al (2014) Bridging the species divide: transgenic mice humanized for type-I interferon response. PLoS One 9(1):e84259
24. Winsauer C et al (2014) Cellular sources of pathogenic and protective TNF and experimental strategies based on utilization of TNF humanized mice. Cytokine Growth Factor Rev 25(2):115–123
25. Strom SC, Davila J, Grompe M (2010) Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity. Methods Mol Biol 640:491–509
26. Nishimura T et al (2013) Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther 344(2):388–396
27. Kakuni M et al (2014) Chimeric mice with humanized livers: a unique tool for in vivo and in vitro enzyme induction studies. Int J Mol Sci 15(1):58–74
28. Belloni L et al (2012) IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 122(2): 529–537
29. Volz T et al (2013) The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 58(5):861–867
30. Dorner M, Ploss A (2011) Deconstructing hepatitis C virus infection in humanized mice. Ann N Y Acad Sci 1245:59–62
31. von Schaewen M, Ding Q, Ploss A (2014) Visualizing hepatitis C virus infection in humanized mice. J Immunol Methods 410: 50–59
32. Giersch K et al (2014) Persistent hepatitis D virus mono-infection in humanized mice is
efficently converted by hepatitis B virus to a productive co-infection. J Hepatol 60(3): 538–544
33. Kawahara T et al (2013) Human cytomegalovirus infection in humanized liver chimeric mice. Hepatol Res 43(6):679–684
34. Chen AA et al (2011) Humanized mice with ectopic artificial liver tissues. Proc Natl Acad Sci U S A 108(29):11842–11847
35. Bissig KD, Grompe M (2013) Response to “Can ‘humanized’ mice improve drug development in the 21st century?”. Trends Pharmacol Sci 34(8):425
36. Peltz G (2013) Can ‘humanized’ mice improve drug development in the 21st century? Trends Pharmacol Sci 34(8):215–224
37. Pearson T, Greiner DL, Shultz LD (2008) Creation of “humanized” mice to study human immunity. Curr Protoc Immunol Chapter 15:p. Unit 15 21
38. Lang J et al (2011) Generation of hematopoietic humanized mice in the newborn BALB/c-Rag2null Il2rgammanull mouse model: a multivariable optimization approach. Clin Immunol 140(1):102–116
39. Sanchez FM et al (2013) Production and characterization of humanized Rag2-/-gammac-/- mice. Methods Mol Biol 1031:19–26
40. Brehm MA et al (2010) Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin Immunol 135(1):84–98
41. Lavender KJ et al (2014) Production of bone marrow, liver, thymus (BLT) humanized mice on the C57BL/6 Rag2(-/-)gammac(-/-)CD47(-/-) background. J Immunol Methods 407:127–134
42. Bernard D, Peakman M, Hayday AC (2008) Establishing humanized mice using stem cells: maximizing the potential. Clin Exp Immunol 152(3):406–414
43. Tu W et al (2011) The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a gammadelta T cell population in humanized mice. J Exp Med 208(7): 1511–1522
44. Drake AC, Chen Q, Chen J (2012) Engineering humanized mice for improved hematopoietic reconstitution. Cell Mol Immunol 9(3):215–224
45. Chen Q, Khoury M, Chen J (2009) Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice. Proc Natl Acad Sci U S A 106(51):21783–21788
46. Strowig T et al (2011) Transgenic expression of human signal regulatory protein alpha in Rag2-/-gammac(c)-/- mice improves engraftment of human hematopoietic cells in humanized mice. Proc Natl Acad Sci U S A 108(32):13218–13223
47. Jarman ER et al (2000) Deficient cytokine response of human allergen-specific T lymphocytes from humanized SCID mice and reconstitution by professional antigen-presenting cells. J Allergy Clin Immunol 105(5):967–974
48. Vuckovic Set al (2008) Compartmentalization of allogeneic T-cell responses in the bone marrow and spleen of humanized NOD/SCID mice containing activated human resident myeloid dendritic cells. Exp Hematol 36(11):1496–1506
49. Marodon G et al (2009) High diversity of the immune repertoire in humanized NOD/SCID mice genetically determined in humans and humanized mice. Eur J Immunol 42(3):760–770
50. Pham HP et al (2012) Half of the T-cell repertoire combinatorial diversity is genetically determined in humans and humanized mice. Eur J Immunol 42(3):760–770
51. Shultz LD et al (2010) Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice. Proc Natl Acad Sci U S A 107(29):13022–13027
52. Rajesh D et al (2010) Th1 and Th17 immune incompetence in humanized NOD/SCID/IL2rgammanull mice. Hum Immunol 71(6):551–559
53. Ippolito GC et al (2012) Antibody repertoires in humanized NOD-scid-IL2Rgamma(null) mice and human B cells reveals human-like diversification and tolerance checkpoints in the mouse. PLoS One 7(4):e35497
54. Watanabe Y et al (2009) The analysis of the functions of human B and T cells in humanized NOD/shi-scid/gammac(null) (NOG) mice (hu-HSC NOG mice). Int Immunol 36(11):1496–1506
55. Timmons LM et al (2010) T cell receptor-CD4+CD8+ regulatory T cells in humanized NOD/SCID/IL2rgamma(null) mice. Exp Hematol 38(4):551–559
56. Pham HP et al (2012) Half of the T-cell repertoire combinatorial diversity is genetically determined in humans and humanized mice. Eur J Immunol 42(3):760–770
57. Rajesh D et al (2010) Th1 and Th17 immune incompetence in humanized NOD/SCID/IL2rgammanull mice. Hum Immunol 71(6):551–559
58. Ippolito GC et al (2012) Antibody repertoires in humanized NOD-scid-IL2Rgamma(null) mice and human B cells reveals human-like diversification and tolerance checkpoints in the mouse. PLoS One 7(4):e35497
59. Watanabe Y et al (2009) The analysis of the functions of human B and T cells in humanized NOD/shi-scid/gammac(null) (NOG) mice (hu-HSC NOG mice). Int Immunol 36(11):1496–1506
60. Timmons LM et al (2010) T cell receptor-CD4+CD8+ regulatory T cells in humanized NOD/SCID/IL2rgamma(null) mice. Exp Hematol 38(4):551–559
61. Pham HP et al (2012) Half of the T-cell repertoire combinatorial diversity is genetically determined in humans and humanized mice. Eur J Immunol 42(3):760–770
62. Rajesh D et al (2010) Th1 and Th17 immune incompetence in humanized NOD/SCID/IL2rgammanull mice. Hum Immunol 71(6):551–559
63. Ippolito GC et al (2012) Antibody repertoires in humanized NOD-scid-IL2Rgamma(null) mice and human B cells reveals human-like diversification and tolerance checkpoints in the mouse. PLoS One 7(4):e35497
64. Watanabe Y et al (2009) The analysis of the functions of human B and T cells in humanized NOD/shi-scid/gammac(null) (NOG) mice (hu-HSC NOG mice). Int Immunol 36(11):1496–1506
65. Timmons LM et al (2010) T cell receptor-CD4+CD8+ regulatory T cells in humanized NOD/SCID/IL2rgamma(null) mice. Exp Hematol 38(4):551–559
66. Pham HP et al (2012) Half of the T-cell repertoire combinatorial diversity is genetically determined in humans and humanized mice. Eur J Immunol 42(3):760–770
67. Rajesh D et al (2010) Th1 and Th17 immune incompetence in humanized NOD/SCID/IL2rgammanull mice. Hum Immunol 71(6):551–559
68. Ippolito GC et al (2012) Antibody repertoires in humanized NOD-scid-IL2Rgamma(null) mice and human B cells reveals human-like diversification and tolerance checkpoints in the mouse. PLoS One 7(4):e35497
69. Watanabe Y et al (2009) The analysis of the functions of human B and T cells in humanized NOD/shi-scid/gammac(null) (NOG) mice (hu-HSC NOG mice). Int Immunol 36(11):1496–1506
70. Timmons LM et al (2010) T cell receptor-CD4+CD8+ regulatory T cells in humanized NOD/SCID/IL2rgamma(null) mice. Exp Hematol 38(4):551–559
58. Kim SS et al (2012) Humanized mice for studying human leukocyte integrins in vivo. Methods Mol Biol 757:509–521
59. Hu Z, Yang YG (2012) Full reconstitution of human platelets in humanized mice after macrophage depletion. Blood 120(8):1713–1716
60. Choi B et al (2011) Human T cell development in the liver of humanized NOD/SCID/IL-2Rgamma(null)(NSG) mice generated by intrahepatic injection of CD34(+) human (h) cord blood (CB) cells. Clin Immunol 139(3):321–335
61. Joo SY et al (2012) Systemic human T cell developmental processes in humanized mice cotransplanted with human fetal thymus/liver tissue and hematopoietic stem cells. Transplantation 94(11):1095–1102
62. Danner R et al (2011) Expression of HLA class II molecules in humanized NOD. Rag1KO.II2RgKO mice is critical for development and function of human T and B cells. PLoS One 6(5):e19826
63. Billerbeck E et al (2014) Insufficient interleukin-12 signalling favours differentiation of human CD4(+) and CD8(+) T cells into GATA-3(+) and GATA-3(+) T-bet(+) subsets in humanized mice. Immunology 143(2):202–218
64. Haji Y et al (2014) Activation of Notch1 promotes development of human CD8(+) single positive T cells in humanized mice. Biochem Biophys Res Commun 447(2):346–351
65. Billerbeck E et al (2011) Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rgamma(null) humanized mice. Blood 117(11):3076–3086
66. Choi B et al (2011) Human B cell development and antibody production in humanized NOD/SCID/IL-2Rgamma(null) (NSG) mice conditioned by busulfan. J Clin Immunol 31(2):253–264
67. Kim M et al (2011) Co-transplantation of fetal bone tissue facilitates the development and reconstitution in human B cells in humanized NOD/SCID/IL-2Rgamma null (NSG) mice. J Clin Immunol 31(4):699–709
68. Huntington ND, Di Santo JP (2008) Humanized immune system (HIS) mice as a tool to study human NK cell development. Curr Top Microbiol Immunol 324:109–124
69. Pek EA et al (2011) Characterization and IL-15 dependence of NK cells in humanized mice. Immunobiology 216(1–2):218–224
70. Chen Q et al (2012) GM-CSF and IL-4 stimulate antibody responses in humanized mice by promoting T, B, and dendritic cell maturation. J Immunol 189(11):5223–5229
71. Li Y et al (2013) Induction of functional human macrophages from bone marrow monocytes by M-CSF in humanized mice. J Immunol 191(6):3192–3199
72. Ding Y et al (2014) FLT3-ligand treatment of humanized mice results in the generation of large numbers of CD141+ and CD1c+ dendritic cells in vivo. J Immunol 192(4):1982–1989
73. Sridharan A et al (2013) Inhibition of megakaryocyte development in the bone marrow underlies dengue virus-induced thrombocytopenia in humanized mice. J Virol 87(21):11648–11658
74. Frecha C et al (2012) A novel lentiviral vector targets gene transfer into human hematopoietic stem cells in marrow from patients with bone marrow failure syndrome and in vivo in humanized mice. Blood 119(5):1139–1150
75. Tanner A et al (2014) Humanized mice as a model to study human hematopoietic stem cell transplantation. Stem Cells Dev 23(1):76–82
76. Bachmaier K et al (1999) Generation of humanized mice susceptible to peptide-induced inflammatory heart disease. Circulation 99(14):1885–1891
77. Eming R et al (2002) Humanized mice as a model for rheumatoid arthritis. Arthritis Res 4(Suppl 3):S133–S140
78. Shultz LD et al (2007) Humanized NOD/LtSz-scid IL2 receptor common gamma chain knockout mice in diabetes research. Ann N Y Acad Sci 1103:77–89
79. King M et al (2008) Humanized mice for the study of type 1 diabetes and beta cell function. Ann N Y Acad Sci 1150:46–53
80. Taneja V, David CS (2010) Role of HLA class II genes in susceptibility/resistance to inflammatory arthritis: studies with humanized mice. Immunol Rev 233(1):62–78
81. Greiner DL et al (2011) Humanized mice for the study of type 1 and type 2 diabetes. Ann N Y Acad Sci 1245:55–58
82. Zayoud M et al (2013) Subclinical CNS inflammation as response to a myelin antigen in humanized mice. J Neuroimmune Pharmacol 8(4):1037–1047
83. Kerekov N et al (2011) Humanized SCID mice models of SLE. Curr Pharm Des 17(13):1261–1266
84. Little MA et al (2012) Anti-proteinase 3 antineutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLoS One 7(1), e28626
85. Brehm MA, Shultz LD (2012) Human allograft rejection in humanized mice: a historical perspective. Cell Mol Immunol 9(3):225–231
86. Coates PT et al (2001) Human myeloid dendritic cells transduced with an adeno viral interleukin-10 gene construct inhibit human skin graft rejection in humanized NOD-scid chimeric mice. Gene Ther 8(16):1224–1233
87. Marcheix B et al (2006) Multiple human mesenteric arterial grafts from the same donor to study human chronic vascular rejection in humanized SCID/beige mice. J Heart Lung Transplant 25(6):675–682
88. Yi S et al (2012) Adoptive transfer with in vitro expanded human regulatory T cells protect against porcine islet xenograft rejection via interleukin-10 in humanized mice. Diabetes 61(5):1180–1191
89. Jacobson S et al (2010) Alloreactivity but failure to reject human islet transplants by humanized Balb/c/Rag2gc mice. Scand J Immunol 71(2):83–90
90. Jung KC et al (2011) In situ induction of dendritic cell-based T cell tolerance in humanized mice and nonhuman primates. J Exp Med 208(12):2477–2488
91. Waldron-Lynch F et al (2012) Analysis of human biologics with a mouse skin transplant model in humanized mice. Am J Transplant 12(10):2652–2662
92. Zheng J et al (2013) Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice. Sci Transl Med 5(168):168ra9
93. Hammad H et al (2002) Monocyte-derived dendritic cells induce a house dust mite-specific Th2 allergic inflammation in the lung of humanized SCID mice: involvement of CCR7. J Immunol 169(3):1524–1534
94. Firouzi R et al (2003) Multiple sclerosis-associated retrovirus particles cause T lymphocyte-dependent death with brain hemorrhage in humanized SCID mice model. J Neurovirol 9(1):79–93
95. Sheu EG et al (2009) Restoration of skeletal muscle ischemia-reperfusion injury in humanized immunodeficient mice. Surgery 146(2):340–346
96. Unsinger J et al (2009) Sepsis-induced human lymphocyte apoptosis and cytokine production in “humanized” mice. J Leukoc Biol 86(2):219–227
97. Vudattu NK et al (2014) Humanized mice as a model for aberrant responses in human T cell immunotherapy. J Immunol 193(2):587–596
98. Escamez MJ et al (2004) An in vivo model of wound healing in genetically modified skin-humanized mice. J Invest Dermatol 123(6):1182–1191
99. Wahl A, Victor Garcia J (2014) The use of BLT humanized mice to investigate the immune reconstitution of the gastrointestinal tract. J Immunol Methods 410:28–33
100. Turnbaugh PJ et al (2009) The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 1(6):6ra14
101. Kashyap PC et al (2013) Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice. Gastroenterology 144(5):967–977
102. Marcobal A et al (2013) A metabolomic view of how the human gut microbiota impacts the host metabolome using humanized and gnotobiotic mice. ISME J 7(10):1933–1943
103. Nochi T et al (2013) Cryptopatches are essential for the development of human GALT. Cell Rep 3(6):1933–1943
104. Chen L et al (1996) Immunoresponses of humanized SCID mice to human lung cancer cells. Chin Med Sci J 11(2):110–112
105. Lando PA et al (1995) Tumor-reactive superantigens suppress tumor growth in humanized SCID mice. Cancer Res 61(5):2177–2182
106. Pateli GK et al (2012) A humanized stromal bed is required for engraftment of isolated human primary squamous cell carcinoma cells in immunocompromised mice. J Invest Dermatol 132(2):284–290
107. Tezuka K et al (2014) An animal model of adult T-cell leukemia: humanized mice with HTLV-1-specific immunity. Blood 123(3):346–355
108. Suciu-Foca N et al (2007) Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. J Immunol 178(11):7432–7441
109. Wege AK et al (2011) Humanized tumor mice—a new model to study and manipulate...
the immune response in advanced cancer therapy. Int J Cancer 129(9):2194–2206

11. Xiang Z et al (2014) Targeted activation of human Vgamma9Vdelta2-T cells controls Epstein-Barr virus-induced B cell lymphoproliferative disease. Cancer Cell 26(4):565–576

112. Zhou Q et al (2014) Humanized NOD-SCID IL2rg-/- mice as a preclinical model for cancer research and its potential use for individualized cancer therapies. Cancer Lett 344(1):13–19

113. Berges BK, Rowan MR (2011) The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment. Retrovirology 8:65

114. Denton PW et al (2012) Generation of HIV latency in humanized BLT mice. J Virol 86(1):630–634

115. Gorantla S, Gendelman HE, Poluektova LY (2012) Can humanized mice reflect the complex pathobiology of HIV-associated neurocognitive disorders? J Neuroimmune Pharmacol 7(2):352–362

116. Deruaz M, Luster AD (2013) BLT humanized mice as model to study HIV vaginal transmission. J Infect Dis 208(Suppl 2):S131–S136

117. Nixon CC et al (2013) HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice. Blood 122(13):2195–2204

118. Denton PW, Garcia JV (2012) Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends Microbiol 20(6):268–274

119. Klein F et al (2012) HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492(7427):118–122

120. Joseph A et al (2010) Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J Virol 84(13):6645–6653

121. Hur EM et al (2012) Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood 120(23):4571–4582

122. Horwitz JA et al (2013) HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A 110(41):16538–16543

123. Halpern-Stromberg A et al (2014) Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice. Cell 158(5):989–999

124. Biswas S et al (2011) Humoral immune responses in humanized BLT mice immunized with West Nile virus and HIV-1 envelope proteins are largely mediated via human CD5+ B cells. Immunology 134(4):419–433

125. Dash PK et al (2012) Long-acting nanofomulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS 26(17):2135–2144

126. Nischang M et al (2012) Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting antiretroviral drugs for treating HIV-1. PLoS One 7(6):e38853

127. Singh M et al (2014) Minocycline attenuates HIV-1 infection and suppresses chronic immune activation in humanized NOD/LsZ-scidIL-2rgamma(null) mice. Immunology 142(4):562–572

128. Balazs AB et al (2014) Vectored immunophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 20(3):296–300

129. Hofer U et al (2013) Pre-clinical modeling of CCR5 knockout in human hematopoietic stem cells by zinc finger nucleases using humanized mice. J Infect Dis 208(Suppl 2):S160–S164

130. Neff CP et al (2011) A topical microbicide gel formulation of CCR5 antagonist maravroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS One 6(6):e20209

131. Terahara K et al (2013) Expansion of activated memory CD4+ T cells affects infectivity of CCR5-tropic HIV-1 in humanized NOD/SCID/JAK3null mice. PLoS One 8(1):e53495

132. Dudek TE, Allen TM (2013) HIV-specific CD8(+) T-cell immunity in humanized bone marrow-liver-thymus mice. J Infect Dis 208(Suppl 2):S150–S154

133. Dudek TE et al (2012) Rapid evolution of HIV-1 to functional CD8(+) T cell responses in humanized BLT mice. Sci Transl Med 4(143):143ra98

134. Zhang L et al (2011) Efficient infection, activation, and impairment of pDCs in the BM and peripheral lymphoid organs during early HIV-1 infection in humanized rag2(-/-)gamma C(-/-) mice in vivo. Blood 117(23):6184–6192

135. Li G et al (2014) Plasmacytoid dendritic cells suppress HIV-1 replication but contribute to
HIV-1 induced immunopathogenesis in humanized mice. PLoS Pathog 10(7): e1004291

137. Palmer BE et al (2013) In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T-cell levels in humanized mice. J Immunol 190(1):211–219

138. Seung E et al (2013) PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads. PLoS One 8(10): e77780

139. Ringpis GE et al (2012) Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice. PLoS One 7(12):e53492

140. Neff CP et al (2011) An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med 3(66):66

141. Salgado M et al (2014) HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice. J Virol 88(6):3340–3352

142. Murooka TT, Mempel TR (2013) Intravital microscopy in BLT-humanized mice to study cellular dynamics in HIV infection. J Infect Dis 208(Suppl 2):S137–S144

143. Bennett MS, Akkina R (2013) Gene therapy strategies for HIV/AIDS: preclinical modeling in humanized mice. Viruses 5(12):3119–3141

144. Legrand N et al (2009) Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe 6(1):5–9

145. Cox J et al (2012) Mosquito bite delivery of dengue virus enhances immunogenicity and pathogenesis in humanized mice. J Virol 86(14):7637–7649

146. Frias-Staheli N et al (2014) Utility of humanized BLT mice for analysis of dengue virus infection and antiviral drug testing. J Virol 88(4):2205–2218

147. Jaiswal S et al (2012) Enhanced humoral and HLA-A2-restricted dengue virus-specific T-cell responses in humanized BLT NSG mice. Immunology 136(3):334–343

148. Jaiswal S et al (2014) Dengue virus infection induces broadly cross-reactive human IgM antibodies that recognize intact virions in humanized BLT-NSG mice. Exp Biol Med (Maywood) 240(1):67–78

149. Mota J, Rico-Hesse R (2011) Dengue virus tropism in humanized mice recapitulates human dengue fever. PLoS One 6(6):e20762

150. White RE et al (2012) EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest 122(4):1487–1502

151. Sato K et al (2011) A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. Blood 117(21):5663–5673

152. Kuwana Y et al (2011) Epstein-Barr virus induces erosive arthritis in humanized mice. PLoS One 6(10):e26630

153. Heuts F et al (2014) T cells modulate Epstein-Barr virus latency phenotypes during infection of humanized mice. J Virol 88(6):3235–3245

154. Fujiwara S (2014) Reproduction of Epstein-Barr virus infection and pathogenesis in humanized mice. Immune Netw 14(1):1–6

155. Antsiferova O et al (2014) Adoptive transfer of EBV Specific CD8+ T cell clones can transiently control EBV infection in humanized mice. PLoS Pathog 10(8):e1004333

156. Hakki M et al (2014) HCMV infection of humanized mice after transplantation of G-CSF-mobilized peripheral blood stem cells from HCMV-seropositive donors. Biol Blood Marrow Transplant 20(1):132–135

157. Banerjee P et al (2010) Adult T-cell leukaemia/lymphoma development in HTLV-1-infected humanized SCID mice. Blood 115(13):2640–2648

158. Kaushansky A et al (2014) Of men in mice: the success and promise of humanized mouse models for human malaria parasite infections. Cell Microbiol 16(5):602–611

159. Wege AK et al (2012) Leishmania major infection in humanized mice induces systemic infection and provokes a nonprotective human immune response. PLoS Negl Trop Dis 6(7):e1741

160. Libby SJ et al (2010) Humanized nonobese diabetic-scid IL2rgammanull mice are susceptible to lethal Salmonella Typhi infection. Proc Natl Acad Sci U S A 107(35):15589–15594

161. Mian MF et al (2011) Humanized mice for Salmonella typhi infection: new tools for an old problem. Virulence 2(3):248–252

162. Berges B, Tanner A (2014) Modeling of human herpesvirus infections in humanized mice. J Gen Virol 95(Pt 10):2106–2117

163. Tanner A et al (2013) Human herpesvirus 6A infection and immunopathogenesis in humanized Rag2(-)/(-) gamma(-)/(-) mice. J Virol 87(22):12020–12028

164. Lee J et al (2013) Engrafted human cells generate adaptive immune responses to...
Mycobacterium bovis BCG infection in humanized mice. BMC Immunol 14:53

165. Heuts F et al (2013) CD4+ cell-dependent granuloma formation in humanized mice infected with mycobacteria. Proc Natl Acad Sci U S A 110(16):6482–6487

166. Ernst W et al (2013) Humanized mice, a new model to study the influence of drug treatment on neonatal sepsis. Infect Immun 81(5):1520–1531

167. Brehm MA et al (2013) Humanized mice for the study of infectious diseases. Curr Opin Immunol 25(4):428–435

168. Lassnig C et al (2005) Development of a transgenic mouse model susceptible to human coronavirus 229E. Proc Natl Acad Sci U S A 102(23):8275–8280

169. Akkina R (2013) New generation humanized mice for virus research: comparative aspects and future prospects. Virology 435(1):14–28

170. Leung C et al (2013) Infectious diseases in humanized mice. Eur J Immunol 43(9):2246–2254

171. Koo GC, Hasan A, O’Reilly RJ (2009) Use of humanized severe combined immunodeficient mice for human vaccine development. Expert Rev Vaccines 8(1):113–120

172. Akkina R (2013) Human immune responses and potential for vaccine assessment in humanized mice. Curr Opin Immunol 25(3):403–409

173. Yu CI et al (2008) Broad influenza-specific CD8+ T-cell responses in humanized mice vaccinated with influenza virus vaccines. Blood 112(9):3671–3678

174. Macchiarini F et al (2005) Humanized mice: are we there yet? J Exp Med 202(10):1307–1311

175. Garcia S, Freitas AA (2012) Humanized mice: current states and perspectives. Immunol Lett 146(1–2):1–7

176. Shultz LD et al (2012) Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol 12(11):786–798